FDA Warns Oft-Quoted Dermatologist For Promoting Investigational Drug
This article was originally published in The Rose Sheet
Executive Summary
FDA's recent warning letter to prominent dermatologist Leslie Baumann for her remarks promoting a not-yet-approved Botox alternative makes a statement early in the year about the rigor the agency is bringing to its public safety mission
You may also be interested in...
Jan Marini Ceases Eyelash Product Sales Due To Allergan Suit, FDA Threat
Jan Marini Skin Research (JMSR) is suspending sales of its two Age Intervention eyelash products in the U.S. - citing an uncertain regulatory environment and the daunting prospect of litigation - and focusing on its core skin-care line and opportunities abroad
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle